ClinicalTrials.gg
CompletedNCT01423253RESOLVE3Updated Apr 8, 2016Results posted

Major Depressive Disorder With Mixed Features - Extension

A Phase 3 interventional study of Lurasidone in Major Depressive Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
801st of 1,323
48 · median 70
Started
2011
with 83 others
Phase 3
240 of 1,500
21 open now
Registered
506th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 801st largest by enrollment of the 1,323 interventional ones that give a count, is one of 84 that started in 2011, is one of 240 in phase 3, and was the 506th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.

Subject has completed 6 weeks of treatment in Study D1050304 (NCT#01421134) or Study D1050305 (NCT#01423240).

Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at baseline (Day 43 in Study D1050304 or D1050305).

Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Lurasidone 20, 40, 60 mg

    Lurasidone 20, 40, or 60 mg/day flexibly dosed

    Drug: Lurasidone

Interventions

  • Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed

    Also known as: Latuda

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)

    Percentage of subjects with treatment emergent adverse events (TEAEs)

    Time frame: 12 Weeks

  2. Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)

    Percentage of subjects with Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: 12 Weeks

  3. Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)

    Percentage of subjects who discontinued due to Treatment Emergent Adverse Events (TEAEs)

    Time frame: 12 Weeks

Secondary outcomes

  1. Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores

    Mean change from baseline to week 12 (LOCF) in Montgomery-Asberg Depression Rating Scale (MADRS) total scores The MADRS is a clinician-rated assessment of the subject's level of depression and consists of 10 items. Each item is rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the ten items and ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: Baseline to12 Weeks

  2. Change From Baseline to Week 12 (LOCF) in CGI-S Score

    The Clinical Global Impression - Severity of illness (CGI-S) score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

    Time frame: baseline to week 12

  3. Change From Baseline to Week 12 (LOCF) in the YMRS Total Score

    The Young Mania Rating Scale (YMRS) is an 11-item instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.

    Time frame: Baseline to week 12

  4. Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score

    The Hamilton Rating Scale for Anxiety (HAM-A) is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.

    Time frame: Baseline to week 12

  5. Change From Baseline to Week 12 (LOCF) in the SDS Total Score

    The Sheehan Disability Scale (SDS) is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline to week 12

07

Results

Posted Oct 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 20, 40, 60 mg
Started48
Completed39
Not completed9
Withdrew: Adverse event2
Withdrew: Lack of efficacy2
Withdrew: Lost to follow-up1
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryPercentage of Subjects With Treatment Emergent Adverse Events (TEAEs)

Percentage of subjects with treatment emergent adverse events (TEAEs)

Time frame:
12 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)
percentage of subjectsLurasidone 20, 40, 60 mg
Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)66.7
SecondaryMean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores

Mean change from baseline to week 12 (LOCF) in Montgomery-Asberg Depression Rating Scale (MADRS) total scores The MADRS is a clinician-rated assessment of the subject's level of depression and consists of 10 items. Each item is rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the ten items and ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
Baseline to12 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores
units on a scaleLurasidone 20, 40, 60 mg
Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores-5.9 ± 12.94
PrimaryPercentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)

Percentage of subjects with Treatment Emergent Serious Adverse Events (TESAEs)

Time frame:
12 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)
percentage of subjectsLurasidone 20, 40, 60 mg
Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)0
PrimaryPercentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)

Percentage of subjects who discontinued due to Treatment Emergent Adverse Events (TEAEs)

Time frame:
12 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)
percentage of subjectsLurasidone 20, 40, 60 mg
Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)4.2
SecondaryChange From Baseline to Week 12 (LOCF) in CGI-S Score

The Clinical Global Impression - Severity of illness (CGI-S) score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

Time frame:
baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 (LOCF) in CGI-S Score
units on a scaleLurasidone 20, 40, 60 mg
Change From Baseline to Week 12 (LOCF) in CGI-S Score-0.47 ± 1.442
SecondaryChange From Baseline to Week 12 (LOCF) in the YMRS Total Score

The Young Mania Rating Scale (YMRS) is an 11-item instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.

Time frame:
Baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 (LOCF) in the YMRS Total Score
units on a scaleLurasidone 20, 40, 60 mg
Change From Baseline to Week 12 (LOCF) in the YMRS Total Score-1.5 ± 6.17
SecondaryChange From Baseline to Week 12 (LOCF) in the HAM-A Total Score

The Hamilton Rating Scale for Anxiety (HAM-A) is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.

Time frame:
Baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score
units on a scaleLurasidone 20, 40, 60 mg
Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score-1.5 ± 6.48
SecondaryChange From Baseline to Week 12 (LOCF) in the SDS Total Score

The Sheehan Disability Scale (SDS) is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).

Time frame:
Baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 (LOCF) in the SDS Total Score
units on a scaleLurasidone 20, 40, 60 mg
Change From Baseline to Week 12 (LOCF) in the SDS Total Score-3.6 ± 9.95

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 20, 40, 60 mg—0/48 (0%)16/48 (33.3%)
Most frequent other events
Most frequent other events
EventLurasidone 20, 40, 60 mg
AkathisiaNervous system disorders5/48
DiarrhoeaGastrointestinal disorders4/48
Upper respiratory tract infectionInfections and infestations4/48
NauseaGastrointestinal disorders3/48
FatigueGeneral disorders3/48
HeadacheNervous system disorders3/48
SedationNervous system disorders3/48

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)Lurasidone 20, 40, 60 mg
<=18 years1
Between 18 and 65 years45
>=65 years2
Age, Continuous
Age, Continuous(Years)Lurasidone 20, 40, 60 mg
Mean42.5 ± 13.42
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 20, 40, 60 mg
Female36
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone 20, 40, 60 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American21
White24
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Lurasidone 20, 40, 60 mg
United States48
08

Study locations

17 sites
  • Birmingham Psychiatry Pharmaceutical Studies, Inc
    Birmingham, Alabama 35226, United States
  • Synergy Clinical Research Center
    Escondido, California 92025, United States
  • Collaborative Neuro Science Network, Inc.
    Garden Grove, California 92845, United States
  • Stanford -VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Florida Clinical Research Center, LLC
    Sarasota, Florida 34201, United States
  • Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders
    Boston, Massachusetts 02114, United States
  • St. Charles Psychiatric Associates/Midwest Research Group
    St. Charles, Missouri 63301, United States
  • Village Clinical Research Inc.
    New York, New York 10003, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Behavioral Medical Research of Staten Island
    Staten Island, New York 10305, United States
  • Psychiatry and Behavioral Sciences, Duke
    Durham, North Carolina 27705, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45408, United States
  • CRI Worldwide - Kirkbride
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Dept. of Psychiatry, UT Southwestern Medical Center
    Dallas, Texas 75390-8849, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 2 years after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2011
First posted
Aug 25, 2011
Start
Sep 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Jan 23, 2014
Results first posted
Oct 14, 2015
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01423253
Responsible party
Sponsor
First posted
Aug 25, 2011
Start date
Sep 2011
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 14, 2015
Last update
Apr 8, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion